Mexico has a very strong broadcasting industry. By 1997, the country had a whopping 31 million radio stations. One of the leading radio stations is Televisa Radio which is managed by Alfonso de Angoitia, the Executive Vice President of Grupo Televisa. Many people also listen to Radio Centro which produces several popular stations in Mexico City. The radio has 20 productions studios enabling it to produce all of its programming. Organización Impulsora de Radio provides programming to several radio stations across Mexico.
Television industry in Mexico
Alfonso de Angoitia also manages Grupo Televisa, the largest television station in Spanish speaking countries. Although the company founded Televisa radio station first, it expanded into television by the 1980s. By the beginning of 2002, Televisa was the largest TV network in Mexico controlling more than 300 stations. About 60% of Grupo Televista’s income comes from the television network, specifically telenovelas. The programmes are not only watched in the Spanish world, but also in the United States where there is a large number of Spanish speaking populations. Grupo Televisa also owns print publications including Edivisa and .A. de C.V, a publishing company producing more than 40 Spanish magazines. Edivista also published magazines such as Cosmopolitan and Elle.
About Alfonse De Angoitia
Alfonso de Angoitia is the executive Vice President of Grupo Televisa. Televisa owns television stations, music labels, mobile phones, and other businesses. Although it was a tough year for most media houses in Mexico, under the guidance of Alfonse Angoitia, Televista still dominates the Spanish speaking world. Angoitia is on the board of Grupo Financiero Banorte and the Chairman of the Board of Trustees of Fundación Kardias. He also seats on the boards of Directors of Univision Communications, Cablevision companies, Cablemas Telecomunicaciones, Operbes (Bestel), International television, AXO Group and the Americas Society.
Amicus Therapeutics is an open American biopharmaceutical organization situated in Cranbury, New Jersey. The organization was opened to the public in the year 2007 under FOLD (NASDAQ) trading symbol. That took place after a 2006 arranged offering and ensuing withdrawal, which would have built up the exchanging symbol as AMTX. It is before their IPO; Amicus was financed by an assortment of investment firms including New Enterprise Associates, Radius Ventures, and Canaan Partners.
Amicus Therapeutics focus is on orphan and rare diseases, especially disorders that are collectively referred as lysosomal storage disorders. The organization’s product enhancement is founded mainly on (CHART®) – Chaperone-Advanced Replacement Therapy platform and has focused on improving enzyme replacement therapies. In 2014, Amicus was seemingly the broadest arrangement of small particle pharmacological chaperones within the pharmaceutical industry.
Amicus Therapeutics is headed toward innovation and healing (https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). Focused on providing vital benefits to the uncommon and orphan disease community, the company’s committed initiative group is the main impetus behind its improvements. Team members are always motivated by others in the uncommon disease society and consistently seek to achieve new statues.
John F. Crowley is the Chairman and CEO of Amicus Therapeutics (YahooFinance). John’s association with biotechnology originates from the 1998 analysis of two of his kids with Pompe malady, a severe and a fatal neuromuscular disorder. John’s drive to get them cured forced him to left his work at Bristol-Myers Squibb and turned into a business person Co-organizer, CEO, and president of Novazyme Pharmaceuticals. The company is a biotech start-up performing researches on new experimental treatments focusing Pompe disease, a process John termed as saving the lives of his kids.
Amicus Therapeutics is utilizing innovative technology platform to create treatments for human genetic ailments by particularly focusing on mutated proteins. The researchers looking into these techniques are devoted to finding upgraded medicines for patients affected by these uncommon maladies. Their enthusiasm energizes advancement and empowers the Amicus Therapeutics team to deliver needed solutions. Amicus Therapeutics takes pride in adopting that strong strategy towards such developments, displaying vigorous biotechnology. Modern technologies are meant to stabilize proteins by novel Enzyme Replacement Therapy or by using pharmacological chaperone.